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Nowadays, Alzheimer’s disease (AD) is a severe sociological and clinical problem.
Since it was first described, there has been a constant increase in its incidence and,
for now, there are no effective treatments since current approved medications have
only shown short-term symptomatic benefits. Therefore, it is imperative to increase
efforts in the search for molecules and non-pharmacological strategies that are capable
of slowing or stopping the progress of the disease and, ideally, to reverse it. The
amyloid cascade hypothesis based on the fundamental role of amyloid has been the
central hypothesis in the last 30 years. However, since amyloid-directed treatments
have shown no relevant beneficial results other theories have been postulated to
explain the origin of the pathology. The brain is a highly metabolically active energy-
consuming tissue in the human body. It has an almost complete dependence on the
metabolism of glucose and uses most of its energy for synaptic transmission. Thus,
alterations on the utilization or availability of glucose may be cause for the appearance
of neurodegenerative pathologies like AD. In this review article, the hypothesis known
as Type 3 Diabetes (T3D) will be evaluated by summarizing some of the data that
has been reported in recent years. According to published research, the adherence
over time to low saturated fatty acids diets in the context of the Mediterranean diet
would reduce the inflammatory levels in brain, with a decrease in the pro-inflammatory
glial activation and mitochondrial oxidative stress. In this situation, the insulin receptor
pathway would be able to fine tune the mitochondrial biogenesis in neuronal
cells, regulation the adenosine triphosphate/adenosine diphosphate intracellular
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balance, and becoming a key factor involved in the preservation of the synaptic
connexions and neuronal plasticity. In addition, new targets and strategies for
the treatment of AD will be considered in this review for their potential as new
pharmacological or non-pharmacological approaches.
Keywords: insulin resistance, obesity, type 2 diabetes mellitus, Alzheimer’s disease, Mediterranean diet,
neuroinflammation and neurodegeneration
INTRODUCTION
Several theories have been in the headlines of the Alzheimer’s
disease (AD) research scene in the last 10 years (Folch et al.,
2013; Alzheimer’s Association, 2016; Dobson, 2017; Hurtado-
Puerto et al., 2018) and, in many of them, it was postulated how
an alteration in a metabolic mechanism runs in parallel, or is
the cause, for the development of the classical features of AD
(Frölich et al., 2015). Eventually, it has led to the understanding
that pathologies like type 2 Diabetes Mellitus (T2DM) and AD,
or conditions like morbid obesity, previously believed to run
independently, are actually highly connected through specific
molecular interactions that evolve in the same direction (de la
Monte, 2012; De Felice et al., 2014).
Despite the hypotheses focus on amyloid and TAU
phosphorylation have dominated the neuropathology of
AD so far, new theories have come to light, in part, due to the
failure of all the developed drugs directed against molecules
related to the amyloidogenic pathway (Gauthier et al., 2016).
It has been described that this failure may be the result of
the complex etiology of AD. As of now, it could be classified
into two subgroups. On the one hand, familial AD in which
genetic alterations of the amyloid precursor protein (APP)
or presenilin-1 (PS-1) are involved, accounting the 3% of
cases of the disease. On the other hand, representing the
remaining 97%, the late onset form of AD (LOAD) which is
associated with advanced age, mutations of the apolipoprotein E
(APOE) ε4 allele, hypertension and hyperlipidaemia, as well
as with coronary disease, T2DM and obesity among other less
determinant factors.
In parallel with AD, obesity has become pandemic in the
Western world and it has shown increased prevalence in most
countries mainly due to changes in nutritional habits and
lifestyle (de la Monte, 2014; Luciano et al., 2015; Kivipelto et al.,
2018). Although the interaction between obesity, aging and AD
is a complex process, there are evidences demonstrating that
obesity and metabolic dysfunctions in middle age substantially
increase the risk of developing AD (Kivipelto et al., 2018).
Thus, studies conducted in the last 20 years support the
hypothesis that deficits in brain insulin and insulin-like growth
factor (IGF-1) signaling mediate cognitive impairment and
neurodegeneration in AD (de la Monte, 2012). As we will
discuss below, the main role of insulin and insulin receptor
pathway in different brain regions as hippocampus and cortex
is mainly related to the maintenance of intracellular energy
levels needed to sustain synaptogenesis and neuronal plasticity.
For this reason, some researchers have even referred to AD
as Type 3 Diabetes (T3D; de la Monte, 2012, 2014; Chami
et al., 2016; Kandimalla et al., 2017; Kang et al., 2017; Tong
et al., 2017). This concept describes a brain-specific pathological
situation in which insulin and IGF resistance is developed
inducing cognitive impairments and neurodegeneration. Insulin
resistance is classically defined as the state in which high
levels of circulating insulin (hyperinsulinemia) are associated to
hyperglycemia, concept that has been extended to other tissues
and organs which show reduced activation of the pathways in
insulin signaling. Therefore, AD and diabetic pathologies share
several common features (Willette et al., 2015), situation in which
adherence to good life habits, especially in terms of motor activity
and diet, may have beneficial effects on cognitive processes
during aging in humans.
From ametabolic outlook, the brain requires a high amount of
energy to maintain its functions, especially for the transmission
of synaptic impulses (Yun and Hoyer, 2000; Hoyer, 2004; Maurer
andHoyer, 2006). Hence, alterations in brain glucosemetabolism
lead to severe dysregulations in cellular function. For example,
a decrease in ATP production and choline acetyltransferase
activity in presynaptic cholinergic neurons reduce the availability
of acetylcholine in the brain which is worsened by the depletion
of citric acid cycle intermediates that are also required for the
synthesis of this neurotransmitter (Hoyer, 2002a,b; Salkovic-
Petrisic et al., 2009). Alterations on its availability could also
trigger a dysfunction in synaptic transmission and affect proper
cognitive function (Hoyer, 2004; Frölich et al., 2015; Fadel and
Reagan, 2016).
This review article focuses on the evidence concerning
the effects of obesity and T2DM in the process of cognitive
loss. Likewise, we discuss throughout the manuscript the
close relationship between alterations at the peripheral level
related to obesity that may favor the risk of developing AD
and the role of amyloid-β (Aβ) generated at the brain level,
which could be an inducer of the onset of T2DM. Since
obesity and metabolic syndrome are modifiable risk factors that
contribute to insulin-resistant diabetes, special emphasis will be
put on their relationship with T3D. Finally, pharmacological
and environmental interventions, such a suitable diet, will also
be discussed as possible strategies to prevent obesity-related
cognitive loss.
PHYSIOLOGICAL ROLE OF INSULIN
BEYOND PERIPHERAL TISSUES
As we mentioned, the classical amyloid and Tau hypotheses of
AD have been challenged by reported evidence that describes
how they may not be the source for the pathology in its
late onset form (Selkoe and Hardy, 2016). It was Dr. Hoyer
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who in 1985 introduced the idea of alterations in brain
metabolism as the source for the appearance of LOAD through
defects in the oxidative degradation of glucose (Hoyer, 2004;
Frölich et al., 2015; Morgen and Frölich, 2015). Specifically,
it has been described that oxidative dysregulation triggers
cellular downstream signaling pathways promoting neuronal
degeneration through the induction of stress in organelles like the
mitochondria and the endoplasmic reticulum. As a consequence,
Aβ and Tau alterations would emerge contributing to the
ongoing cognitive loss. This could explain why drugs focusing
on Aβ and Tau have proven useless so far since they would be
targeting a consequence or aggravator of the pathology but not
its root.
In addition to this, in recent years it has been demonstrated
that insulin receptors (IRs) and their ligand hormone play a
more relevant role in the brain than was previously thought.
Specifically, several studies have reported presence of IRs
in hippocampus, cerebral cortex, cerebellum and choroidal
plexus of the mammalian brain (Hoyer, 2004; de la Monte
et al., 2006) and especially in postsynaptic terminals (Abbott
et al., 1999). It has been demonstrated that insulin levels
become strongly reduced in these regions during aging and
in sporadic AD (Ramalingam and Kim, 2014). Indeed, insulin
is preferentially transported to the brain through the blood-
brain barrier (BBB) in a receptor-mediated mechanism and
its availability is critical for the activation of brain IR. In
this aspect, it has been proposed that brain insulin has a
neuroprotective capacity against the accumulation of senile
plaques, by regulating Aβ peptide levels and preventing the
binding of Aβ oligomers to synapses (Zhao et al., 2008;
De Felice et al., 2009, 2014; Lyra E Silva et al., 2019).
Interestingly, AD preclinical models show that preventing IR
inhibition enhances Protein kinase B (AKT) signaling, which is
involved in cell proliferation, cell growth, protein synthesis and
inhibition of apoptosis, but also in the hyperphosphorylation
of Tau through the control of the glycogen synthase kinase 3β
(GSK3β; El Khoury et al., 2014). By contrast, insulin deficits
have been linked to the inhibition of several phosphatases
involved in Tau dephosphorylation (El Khoury et al., 2014).
Finally, it has been proven that insulin signaling pathway
is also involved in the modulation of neuroinflammatory
processes and vascular inflammation (Chen and Zhong, 2013).
Likewise, insulin modulation acts through the mitogen-activated
protein kinase (MAPK) pathway, which plays an important
role in cell differentiation, cell proliferation, apoptosis as well
as inflammation. As we will discuss below, the activation
of some c-JUN N-terminal Kinases (JNKs) should be a
key factor linking insulin signaling to synaptogenesis failure
(Huang et al., 2017; Pomytkin et al., 2018).
In 2000, Bru and co-workers published an interesting article
demonstrating that brain IR is involved in the metabolic control
of peripheral tissues through the generation of a murine model
with a specific deletion of the neuronal IR gene (NIRKO mice;
Bru et al., 2000). This inactivation resulted in insulin resistance
at the central nervous system (CNS) but mice also developed
obesity, combined with hyperphagia, an increase of leptin and
insulin concentrations in plasma, as well as the development
of hypertriglyceridemia. In agreement with this, Obici and co-
workers demonstrated that a decrease in the hypothalamic IR
expression is enough to induce several key features of metabolic
syndrome (Obici, 2009). Hence, insulin resistance in the brain
would be involved in the pathophysiology of obesity and T2DM
in the peripheral tissues.
All these experimental data indicate that brain IR plays
a key role in: (i) regulation of cognitive processes through
hippocampal IR; and (ii) regulation of peripheral glucose
metabolism. Consequently, restoration of normal insulin levels
and prevention of brain insulin resistance may be a therapeutic
strategy for delaying cognitive loss in AD (Biessels, 2013;
Ramalingam and Kim, 2014).
TOWARDS BRAIN INSULIN RESISTANCE
IN LATE ONSET AlZHEIMER’S DISEASE
Recently, Castellani et al. (2019) proposed, in an excellent review
on AD therapeutics, that it was very reasonable to conclude
that the amyloidogenic pathway is very closely related to AD,
however, the important role of other players was suggested
into the origin of the pathology since the clearance of Aβ
protein was not enough to modify the evolution of the disease.
Furthermore, pharmacological strategies targeting Aβ-related
biomarkers like BACE1 inhibitors or anti-Aβ antibodies, have
failed to cure or halt LOAD (Cummings et al., 2018). Hence,
new strategies should be designed to complement the actual
therapeutic proposals that, so far, have been mainly focused on
the amyloid hypothesis.
One of the first reviews that criticized the paradigm of
the amyloid cascade overactivation as the origin of AD was
written by one of the co-authors that first described this central
hypothesis (Cleary et al., 2005; Hardy, 2009; Selkoe and Hardy,
2016). But, back in 1985, as it was previously mentioned, before
the installment of the amyloidogenic hypothesis, Dr. Siegfried
Hoyer had already proposed the concept of central insulin
resistance and altered insulin signaling in LOAD (Frölich et al.,
2015; Hoyer, 2002b, 2004; Morgen and Frölich, 2015). Later on,
Dr. de la Monte published a series of articles about the metabolic
hypothesis of AD, and became one of the main defenders
of the so-called ‘‘brain insulin resistance’’ or T3D hypothesis
(de la Monte et al., 2006; de la Monte and Wands, 2008;
Chami et al., 2016; de la Monte, 2017). In these experiments,
the intracerebral administration of streptozotocin (STZ) was
used as an experimental model to induce LOAD-like cognitive
impairments in rodents, allowing to study this theory deeper
(de la Monte et al., 2006; Correia et al., 2011; Salkovic-Petrisic
et al., 2013; Tong et al., 2017). The research by Dr. de la Monte
in AD patients also proved significant reductions in insulin and
IGF-1 receptor levels in the frontal cortex, hippocampus, and
hypothalamus (Steen et al., 2005), reinforcing the idea of T3D.
Likewise, Cardoso et al. (2017) suggested the term ‘‘diabesity’’ to
explain the presence of bothmetabolic and cognitive affectations.
In parallel with these observations, results from epidemiologic
studies contributed to reinforce the proposed concept
of T3D. Doubtlessly, one of the most important is the
Rotterdam’s study (Ott et al., 1999; Schrijvers et al., 2010;
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Luciano et al., 2015). This project has investigated the connection
between T2DM and LOAD for almost a decade, revealing that
those patients diagnosed with T2DM had higher risk of
developing dementia. Subsequent clinical and epidemiological
studies have confirmed this association, by demonstrating
that alterations of metabolic parameters related to glucose
metabolism were associated with cognitive loss (Talbot et al.,
2012; Biessels, 2013; Walker and Harrison, 2015). Moreover,
in a clinical study in patients with AD and hyperinsulinemia,
Willette et al. (2015) demonstrated that insulin resistance
increased the number of Aβ depositions in the brain. It has
also been reported that neurons from AD patients exhibit an
insulin mRNA expression four times lower than normal in
the hippocampus and two times lower than normal in the
hypothalamus (Chen and Zhong, 2013). This situation would
be aggravated by the disruption of the activity of astrocytes
forming the BBB. Likewise, patients with AD show alterations
in the transport of this hormone into the brain (Molofsky et al.,
2012; An et al., 2018). It is noteworthy to point out that, in
addition to the lower availability of insulin in the brain, cerebral
insulin resistance is another pathophysiological feature of AD.
Thus, it seems that insulin signaling could have a key role in
cognitive loss.
In 2014, the Hisayama’s study showed, through the analysis
of microarrays, modifications in the normal expression of genes
related to T2DM in AD brains, especially in the hippocampus
(Hokama et al., 2014). More recent studies have also reinforced
the notion of an insulin resistance having a key role in
AD’s pathogenesis. For instance, An et al. (2018) reported a
strong association between impairments in glucose metabolism
and increased glucose concentrations in areas sensible to Aβ
deposition and neurofibrillary pathology. The authors suggested
that AD is associated with a failure in neuronal glucose
utilization, which is mediated by an alteration in glycolysis. The
authors argued that three enzymes involved in the glycolysis
(hexokinase, phosphofructokinase, and pyruvate kinase) showed
significant reduction in their activity in AD. In turn, in the
Whitehall II clinical study, Singh-Manoux et al. (2018) reported
that obesity (BMI >30 kg/m2) at 50 years of age is a risk factor
for AD. However, the association decreased with increasing
age, indicating that this association is modified by age and
obesity, being midlife obesity the riskiest stage for dementia
(Singh-Manoux et al., 2018). In another interesting clinical study,
Ahmed et al. (2017) reported a bidirectional association between
T2DM and LOAD. Besides, they reported that Memantine—a
drug which is currently used in AD treatment- showed an
ameliorating effect on T2DM. This is in accordance with
results published by our research group and others, where
the benefits of Memantine administration were demonstrated
in a mixed murine model of T2DM and AD (Sato and
Morishita, 2013; Shinohara and Sato, 2017; Ettcheto et al., 2018b;
Deng et al., 2019).
Regarding other preclinical studies, have been shown that
hyperglycemia raises Aβ levels in the interstitial fluid (ISF) by
altering neuronal activity. It seems that high glucose metabolism
can alter ATP-sensitive potassium (KATP) channels, which are
the link between changes in metabolism, neuronal activity and
ISF Aβ (Macauley et al., 2015; Stanley et al., 2016). In turn,
Grillo et al. (2015) reported that the administration of viral
vectors expressing an antisense sequence of the rat brain IR
caused cognitive impairments. Thus, they generated a specific rat
model of altered brain insulin signaling associated to cognitive
loss. These results are of great relevance since demonstrated that
selective insulin resistance at the hippocampal level contributes
directly to the development of cognitive deficits observed in
patients with metabolic disorders such as T2DM and obesity
(Fadel and Reagan, 2016).
Finally, among other risk factors likely to favor the
development of sporadic AD, the mutation of the APOE4 allele
has recently shown an intriguing association with insulin
resistance. Thus, it has been suggested that APOE4 impairs IR
trafficking by trapping it in endosomes, leading to impaired
insulin signaling (Zhao et al., 2017). The APOE gene ε4 allele is
so far considered the strongest genetic risk factor for AD. These
findings are relevant to explain the correlation between T2DM
and LOAD (Peila et al., 2002). In addition, this implies that the
presence of APOE4 allele and T2DM could act synergistically in
AD pathogenesis. Accordingly, the highest risk for AD and the
most severe neuropathology is found in individuals with both
diabetes and the APOE4 mutation (Peila et al., 2002).
OBESOGENIC DIET AS A RISK FACTOR
FOR COGNITIVE IMPAIRMENT
Previous studies reported that obesity is associated to memory
impairment through insulin resistance in both, young people
(Cheke et al., 2016) and cognitively normal older people
although the underlying mechanisms remain unclear (Hargrave
et al., 2016; Kivipelto et al., 2018). Likewise, in the older
people an association between obesity and brain atrophy has
been described (Raji et al., 2010). It is widely accepted that
obesity favors the emergence of metabolic syndrome affecting
peripheral tissues such as liver, pancreas and adipocytes (Cardoso
et al., 2017; Kang et al., 2017; Kothari et al., 2017). We have
already discussed the observations based on the experimental
use of STZ to induce diabetes in rats (de la Monte et al.,
2006; de la Monte, 2017). This toxic compound can trigger
Type 1 diabetes mellitus by killing insulin-producing cells in
the pancreas and, at lower doses, can lead to T2DM and
related alterations (Correia et al., 2011; Salkovic-Petrisic et al.,
2013; Tong et al., 2017). Indeed, lower STZ doses have been
involved in neuronal loss, neuroinflammation, oxidative stress
and accumulations of phospho-TAU and Aβ in cortical-limbic
structures that characteristically degenerate in AD, leading to
impaired spatial learning and memory (Correia et al., 2011).
Since STZ is a nitrosamine, a chemical compound that can
be found in many foods and other consumables, the question
is: could diet be directly involved in the exacerbation of
cognitive decline in LOAD? Indeed, several studies suggest
that environmental exposure to food additives may play a
critical role in the pathogenesis of AD (de la Monte et al.,
2018, 2019). In light of the unstoppable increase in LOAD
prevalence rates and the widespread use of nitrites and
nitrates in foods and agricultural products over the past
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30–40 years, the impact of exposure to dietary components
as nitrosamines should be reviewed in relation to T3D
(de la Monte et al., 2018).
Several studies suggest that there is a link between calorie
intake from diets rich in saturated fats or high fat diets (HFD)
and the resulting obesity and cognitive deficits (Kohjima et al.,
2010; Yarchoan et al., 2014; Pratchayasakul et al., 2015; Moser
and Pike, 2017; Sah et al., 2017). By contrast, moderate dietary
restriction has been found to improve cognition and, indeed,
life expectancy (Parrella et al., 2013). These findings are the
reason why studies on the interaction metabolism-AD have
gained a great deal of interest. Thus, it is not surprising that HFD
has been associated with a large number of metabolic diseases,
such as obesity, systemic insulin resistance, metabolic syndrome
and T2DM (de la Monte, 2014; Ferreira et al., 2014; Cardoso
et al., 2017). Nuzzo et al. (2015) provided evidence that obesity
and insulin resistance are involved to inflammation, adipokine
dyshomeostasis, oxidative stress and mitochondrial dysfunction,
all of them being mechanisms that favor neurodegeneration. In
those experiments, mice fed with an HFD showed elevated levels
of APP and Aβ40/Aβ42, BACE, GSK3β and TAU proteins, all
involved in APP processing and Aβ accumulation. In light of
these results, it is clear that the exposure of rodents to a HFD
damages their brain in a similar manner to the hallmarks of
AD (Pratchayasakul et al., 2015; Ettcheto et al., 2016; Sah et al.,
2017). In another study, Bocarsly et al. (2015) also reported
negative consequences of HFD in rats. Specifically, HFD has
been associated to alterations in brain cortical dendritic spines
and a decrease in presynaptic and postsynaptic protein levels,
which was related to behavioral cognitive deficits in working
memory and cognition (Bocarsly et al., 2015). In turn, Kothari
and colleagues reported that HFD may impair brain insulin
signaling promoting neuroinflammation, formation of Aβ
plaques and neurofibrillary tangles, as well as loss of synaptic
plasticity (Sallam et al., 2015). In the same line, Kohjima et al.
(2010) also reported that diet-induced insulin resistance is
associated with reduced neuronal insulin receptor signaling,
leading to an increase in Aβ levels and cognitive loss in the
brain of Tg2576 mice. Likewise, an hypercaloric diet increases
brain Aβ levels and cognitive alterations in APPswe/PS1dE9
(APP/PS1) mice (Petrov et al., 2015). Similarly, the same murine
model under a HFD at an early pre-symptomatic disease
stage (3 months old) showed an increase in Aβ1–42 peptide,
a decrease in Protein Kinase A (PKA) levels and alterations in
the c-AMP Response Element Binding (CREB)/N-methyl-D-
aspartate receptor 2B (NMDAR2B)/Peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α)
pathway (Sheng et al., 2012; Ettcheto et al., 2016; Katsouri
et al., 2016; Wang et al., 2017). This mechanism involves
the attenuation of the forkhead-like transcription factor 1
(FoxO3a) expression.
There can be found some other several preclinical studies
in which the exposure to HFD is associated with a decline
in cognitive function. In many of these studies, HFD-induced
alterations in peripheral insulin sensitivity lead to a central
insulin resistance and biochemical changes related to increased
Aβ deposition and neurofibrillary tangle formation (Kothari
et al., 2017). For instance, Chua et al. (2012) demonstrated that a
reduction in insulin signaling usually precedes the accumulation
of Aβ peptide in APP/PS1 mice. In another study developed
by our research group, long-term exposure to HFD favored the
appearance of Aβ depositions in the brain of C57BL/6J mice
(Busquets et al., 2017). This is an intriguing observation because,
since these wild-type mice do not develop cognitive loss per se,
our results implied that HFD maintained for a long time could
be enough to damage brain.Moreover, HFD caused alterations in
different cell processes, such as normal autophagy and apoptosis,
and also enhanced an inflammatory reaction that leads to a
decrease in the neuronal precursor cells (Busquets et al., 2017).
Taken altogether, the above-mentioned results reinforce the
hypothesis of a metabolic etiology of AD in its sporadic and late
onset form. They also confirm that HFD favors Aβ depositions in
the brain, a key feature of this disease. In this point, an important
question arises: what is the molecular link between diet, T2DM
and cognitive impairment? In this regard, Osborne et al. (2016)
reported that intrahippocampal infusion of an Aβ33–42 gamma
antibody reversed cognitive impairment in rats withHFD-related
cognitive loss. Hence, these results stressed the role of soluble Aβ
in obesity-mediated cognitive loss and they are in agreement with
previous studies hypothesizing that diffusible Aβ oligomers are
responsible for neural dysfunction leading to AD (Walsh et al.,
2005; Tarasoff-Conway et al., 2015; Xia et al., 2016; Bu et al., 2018;
Hurtado-Puerto et al., 2018). Accordingly, Aβ could be a possible
connection between the metabolic and the classical amyloid
hypotheses of AD, since it binds to the IR and may trigger
its internalization at the post-synaptic level, thereby blocking
glutamatergic neurotransmission (De Felice et al., 2014; Ribe and
Lovestone, 2016; Ahmed et al., 2017). In addition, Aβ oligomers
have been found to inactivate IRs via the JNKs pathway through
a mechanisms that is comparable to the established peripheral
effect of JNKs on IRs in T2DM (Zhao et al., 2008; Ma et al., 2009;
Freiherr et al., 2013; Lyra E Silva et al., 2019).
WHICH CAME FIRST: OBESITY OR Aβ?
THE “CHICKEN OR THE EGG” CAUSALITY
DILEMMA IN LOAD
Among the plethora of functions performed by the CNS, it also
plays a key role in the glucose homeostasis. Indeed, different
glucose sensors signals are integrated and processed by the CNS,
involved in regulating glucose production, pancreatic hormonal
secretion and glucose uptake, maintaining the balanced glucose
levels against changing conditions (Cai, 2013; Zheng et al., 2018).
The hypothalamus controls several regulatory mechanisms of
peripheral glucose homeostasis through the control of various
signals from organs and tissues involved in digestion, absorption
and storage of nutrients. Neurons responsible for the CNS
metabolic balance are found in a sub-region of the ventromedial
hypothalamus, called the arcuate nucleus (aRC). They express
anabolic peptides such as the neuropeptide Y and agouti-
related peptide (aGRP), as well as proopiomelanocortin, which
is the precursor of numerous biologically active peptides,
including the α-melanocyte stimulating hormone (αMSH) which
Frontiers in Aging Neuroscience | www.frontiersin.org 5 September 2019 | Volume 11 | Article 236
Folch et al. Brain Insulin Resistance in Alzheimer’s
favors catabolism (Obici et al., 2002; Obici, 2009; Sandoval
et al., 2009). This complex machinery includes hormones
like insulin, adipokines as leptin, molecules like ghrelin or
gut peptides as Glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP; De Felice et al.,
2014; Fasshauer and Blüher, 2015). Insulin decreases blood
glucose concentrations by suppressing glucose production and
upregulating its absorption by peripheral tissues (such as skeletal
muscles and fat). Leptin exerts anorexigenic effect when it is
released from fat tissue, whereas GLP1 and GIP are secreted
from the pancreas during feeding inducing the increase glucose-
dependent insulin secretion. However, the CNS also produces
some of these molecules and receptors, which can be found in
many of its areas including the aRC. Surprisingly, in addition to
be capable of trespassing the BBB, insulin can also be secreted
autonomously by the brain (Warren et al., 2012; Folch et al., 2013;
Nuzzo et al., 2015).
In light of the above-mentioned, it is crucial to understand the
potential mechanisms linking AD to obesity and T2DM. Among
the hypotheses suggested, there is mounting data supporting an
early involvement of Aβ-mediated alterations in hypothalamus
leading to peripheral metabolic dysregulation. This may occur
even before the appearance of cognitive loss symptoms. In
this line of thought, Arrieta-Cruz and colleagues reported that
direct administration of Aβ25–35 in the hypothalamus disrupts
the regulation of glucose oxidation (Arrieta-Cruz et al., 2015;
Arrieta-Cruz and Gutiérrez-Juárez, 2016). In turn, Clarke and
colleagues also reported that intracerebroventricular injections
of Aβ oligomers trigger peripheral systemic glucose intolerance
and insulin resistance in rodents, through a process related with
hypothalamic inflammation (Clarke et al., 2015, 2018; Lourenco
et al., 2019). Hence, these data reinforce the notion that Aβ affects
hypothalamic function, altering peripheral metabolic control and
whole-body homeostasis (Obici et al., 2002; Sandoval et al., 2009;
Figure 1). Likewise, cerebral Aβ could traverse the BBB and
affect peripheral tissues, leading to peripheral insulin resistance.
In accordance, it has been demonstrated that plasma Aβ induces
insulin resistance in hepatocytes by activating Janus Kinase 2
(JAK2)/STAT3/Suppressor of Cytokine Signaling-1 (SOCS-1)
signaling pathway in APP/PS1 mice, suggesting an important
role of peripheral Aβ in the regulation of glucose metabolism
(Zhang et al., 2013). Moreover, Aβ accumulation also occurs in
the pancreas and skeletal muscle which may induce alterations
on peripheral glucose metabolism (Roher et al., 2009; Miklossy
et al., 2010; Kulas et al., 2017). Likewise, peripheral tissues
such as heart, liver, testis, aorta, lung, intestines, skin, as well
as the adrenal, salivary, and thyroid glands also produced Aβ
peptide (Wang et al., 2017; Wijesekara et al., 2017). Although the
implications of peripheral Aβ are still unknown, a contribution
of a dynamic maintenance of Aβ levels throughout the body
should not be discarded (Selkoe andHardy, 2016; Bu et al., 2018).
Indeed, platelets are a peripheral source of APP and they are able
to generate Aβ in a similar manner than neurons, skin fibroblasts,
skeletal muscles and cerebrovascular smooth muscle cells (Roher
et al., 2009). Hence, peripheral alterations in APP metabolism
might constitute a systemic and also a CNS problem in LOAD,
hypothesizing that these peripheral Aβ could also contribute to
T2DM pathophysiology (Kuo et al., 2000; Shinohara and Sato,
2017). In any case, some recent studies have provided data
on the complex mechanistic interactions between T2DM and
AD. For instance, Plucínska et al. (2016) demonstrated, using a
neuron-specific human BACE1 knock-in mouse model (PLB4)
that increased neuronal BACE1 is sufficient to alter systemic
glucose metabolism. Therefore, this study also confirms that
brain Aβ leads to a peripheral T2DM process. In turn, Sallam
and colleagues developed an adipocyte-specific ecto-nucleotide
pyrophosphate phosphodiesterase over-expressing transgenic
(AtENPP1-Tg) as metabolic syndrome and systemic insulin
resistance animal model (Sallam et al., 2015). These mice showed
changes in lipid composition of hippocampal synaptosomes,
impaired basal synaptic transmission as well as down-regulation
of IR expression. The authors concluded that hippocampal
molecular and functional integrity become affected by the
IR and lipid composition, describing a potential mechanism
responsible for the cognitive impairments associated with
metabolic syndrome (FFA) and T2DM (Sallam et al., 2015).
Therefore, the process of cognitive impairment could start
in peripheral tissues or, at least, could be exacerbated by
potential interactions between peripheral tissues and brain.
Excessive caloric intake leads to hypertrophy or hyperplasia
of adipocytes, resulting in adipose tissue expansion. As a
consequence, there is an increased secretion of adipokines,
including a broad range of cytokines and chemokines, triggering
the recruitment of inflammatory cells to the tissue and a second
wave of inflammatory mediators release (Fasshauer and Blüher,
2015). Among these mediators, TNFα and some angiogenic
factors could inhibit peripheral insulin signaling. Additionally,
other proinflammatory cytokines such as interleukin IL1b
and IL6, are able to cross the BBB and exacerbate brain
inflammation together with proinflammatory factors produced
by microglial cells (Warren et al., 2012; Fasshauer and Blüher,
2015). In turn, high blood insulin concentrations trigger
an excessive release of FFA from adipocytes to liver and
muscles, leading to exacerbated inflammatory responses and
increased accumulation of Aβ. By contrast, hyperinsulinemia
decreases insulin transport into the brain. Thus, adipose
tissue extension in obesity and T2DM could trigger cognitive
loss, reflecting the relationship between the adipose tissue
and the brain, thus impacting on its function (Fasshauer
and Blüher, 2015). Conversely, hypothalamic soluble Aβ and
Tau phosphorylation may contribute to the impairment of
the control of peripheral glucose metabolism in patients
with AD (Cai, 2013; Chen and Zhong, 2013). This could
be mediated by a direct effect of Aβ on central IR and
by a mechanism mediated by Tau hyperphosphorylation,
which increases intraneuronal insoluble insulin aggregates and
downregulates IRs, leading to insulin resistance (El Khoury et al.,
2014; Marciniak et al., 2017; Rodriguez-Rodriguez et al., 2017;
Gonçalves et al., 2019).
Finally, a study performed by Banks et al. (2018) introduced
an additional mechanism whereby metabolic syndrome
contributes to cognitive impairment. The authors reported
that triglycerides cross the BBB leading to brain leptin and
insulin receptors resistance, which has a negative effect on
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FIGURE 1 | Obesity, caused by a sedentary life or a high fat diet, increases the risk of type 2 Diabetes Mellitus [T2DM; Metabolic hypothesis of Alzheimer’s disease
(AD)]. This condition increases the risk of cognitive loss and AD through mitochondrial alteration, neuroinflammation, Aβ production and brain insulin resistance. At
the brain level Aβ oligomers trigger peripheral systemic glucose intolerance and insulin resistance in rodents, through a process of hypothalamic neuroinflammation
(Clarke et al., 2015, 2018; Lourenco et al., 2019). Likewise, cerebral Aβ could traverse the blood-brain barrier (BBB) and affect peripheral tissues, leading to a
peripheral insulin resistance. This mechanism would behave in a positive feedback loop that would worsen over time.
cognition (Banks et al., 2018). These results confirm that
modulation of peripheral metabolism, for example lowering
elevated levels of triglycerides in the blood, could be a strategy
to treat obesity and cognitive impairment associated with CNS
resistance to leptin and insulin. In another interesting study,
Moreno-Gonzalez et al. (2017) demonstrated that IAPP (amylin)
aggregates are able to enhance the aggregation of Aβ, providing a
potential additional link between AD and T2DM. Clearly, future
studies will provide further keys to understand the relation
between cognitive loss, obesity and T2DM (Vazquez-Valls et al.,
2011; Mukherjee et al., 2017).
ROLE OF JNK1 AS A TARGET FOR
DIABETES TYPE 2 AND OBESITY
Obesity triggers inflammatory processes that spread through the
human body affectingmultiple organs and tissues. Consequently,
brains of HFD-exposed mice showed neuroinflammation and
glial responses (Busquets et al., 2017). In a very recent review
on this topic, authors described how HFD, western diet or
sugars cause obesity-derived neuroinflammation, affecting brain
structures such as the hippocampus, hypothalamus, cortex,
brainstem, or amygdala (Guillemot-Legris et al., 2016). Similarly,
AD patients exhibit significantly higher concentrations of
IL-6 and TNFα in peripheral blood (Swardfager et al., 2010;
Zheng et al., 2018).
Regarding the possibility that peripheral chronic
inflammation can contribute to cognitive decline and cause
LOAD, data show that IR tyrosine kinases trigger the activation
of the RAS/MAPKs pathway. This superfamily includes
extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2),
p38 and c-JNKs (Coffey, 2014). Moreover, it has been reported
that ERK1 and ERK2 play a very significant role in the control
of synapses in the learning and memory processes, while the
contribution of p38 in associative learning has been described
marginally (Sherrin et al., 2010, 2011). Likewise, CREB is
the main target of ERK and has a pivotal role in long-term
memory and synaptic plasticity in the hippocampus (Suzuki
et al., 2011; Teich et al., 2015). Regarding to JNK family, it
consists of three members, JNK1 (Mapk8), JNK2 (Mapk9) and
JNK3 (Mapk10; Sabio and Davis, 2010; Auladell et al., 2017;
Solinas and Becattini, 2017). It has been proposed that the
JNKs are involved in memory formation during learning under
stressful conditions through the regulation of their activity
(Coffey, 2014). Short-term activation of JNKs will temporarily
boost memory performance, whereas prolonged activation of
JNKs may be a contributing factor to memory deficit and even
neurodegeneration (Sherrin et al., 2011). The pro-inflammatory
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cytokine TNF-α activates JNK1 (Sabio and Davis, 2010; Solinas
and Becattini, 2017). Indeed, it has been shown that JNKs are
activated in obese humans, thus, JNK1 could be implicated in
the mechanism of obesity-induced insulin resistance (Belgardt
et al., 2010). Therefore, the characterization of JNK isoforms
in the hippocampus and their role in memory processes seems
paramount to understand the links among obesity, T2DM and
LOAD (Solinas and Becattini, 2017).
In the hippocampus, JNKs have both presynaptic and
postsynaptic localizations and can regulate proteins from
synaptic vesicles, such as synaptotagmin-4 (Sherrin et al., 2010;
Nisticò et al., 2015). JNKs also regulate second messenger
systems such as cytosolic phospholipase A, cytoskeletal elements
(i.e., MAP2, TAU), nuclear hormone receptors (such as the
glucocorticoid receptor) or transcription factors, including
c-Jun (a member of the activator protein-1, AP-1), activator
transcription factor (ATF)-2, CREB (calcium/cAMP) and Elk-1
(Sabio and Davis, 2010; Kant et al., 2013). Hence, all these
substrates are potential JNKs targets during the learning process.
Moreover, as previously mentioned, JNKs may be central
mediators of many of the deleterious consequences of obesity,
such as impaired glucose metabolism and insulin resistance
(Belgardt et al., 2010). This hypothesis was proposed after
exposing JNK1 knockout mice to an HFD. Surprisingly, these
animals were protected from the development of impaired
glucose tolerance and insulin resistance (Pal et al., 2016).
Indeed, activated JNK1 phosphorylates the insulin receptor
substrate 1 (IRS-1) in the serine residues (IRS-1pSer), blocking
the insulin pathway and causing a peripheral resistance to
this hormone (Solinas and Becattini, 2017). Phosphorylation
in S307 is a mechanism by which the activation of JNK can
directly antagonize insulin action. Therefore, phosphorylation
of IRS1 following the activation of JNK1 has a key role in the
insulin resistance mechanism and obesity process in mammals.
Likewise, the diabetic status alters the signaling pathway
downstream of IR. Among others, it is relevant the energy
alteration sensing pathway comprising the AMP-activated
protein kinase (AMPK)/sirtuin (SIRT)/peroxisome proliferator-
activated receptor-γ coactivator α (PGC-1α; Fernyhough, 2015).
In fact, the intracellular ATP/ADP balance is regulated by
AMPK, which acts as a master sensor that, in turns, also control
the glucose and fatty acids consumption, and the mitochondrial
biogenesis through PGC-1α activity. The energy balance inside
the hippocampal neurons allows for the formation, maintenance
and reorganization of synapses, all of them critical processes
for brain development and appropriate responses generation
from neuronal circuits to environmental challenges (Cheng
et al., 2012). These authors demonstrated how PGC-1α
activity increases dendritic spines and enhances the molecular
differentiation of synapses in cultured hippocampal cells
(Figure 2). Then, in light of evidences, it could be hypothesized
PGC-1α as a molecular link between metabolic alterations
involving brain diabetic status and cognitive impairment.
In addition, other kinases such as nuclear kappa-β kinase
inhibitor (IKK) play a crucial role in the development of
insulin resistance associated with obesity, in both peripheral
and CNS (Sabio and Davis, 2010; Kant et al., 2013; Nisticò
et al., 2015). Likewise, recent studies suggest that activated
protein RNA kinase, also known as protein kinase R (PKR),
plays an important role in insulin resistance induced by a HFD
diet (Taga et al., 2018). Based on this activation sequence,
JNK1 modulation looks like a promising molecule for future
development of novel therapeutic targets aiming to prevent
T2DM. Consequently, selective inhibitors like Licochalcone A,
may be suitable approaches to treat T2DM-related cognitive loss
(Busquets et al., 2018).
Unfortunately, there is a lack of natural or synthetic molecules
capable to modulate the activity of JNKs so far. Among the
extensive effort in exploring therapeutic interventions focusing
on JNK activity, the compound SP600125, a JNK inhibitor,
has been the best characterized (Gao et al., 2017). However,
the application of SP600125 is very limited due to its low
target selectivity, and its clinical efficacy is restricted due to its
poor aqueous solubility (Gao et al., 2017). Notwithstanding,
selective, water-soluble and brain-penetrant JNK inhibitors
have been recently tested (Kumar et al., 2016). I.P. and i.c.v.
administrations of SR11935, SR3306 and JNK2/3 isoform-
selective inhibitors indicated possible anorectic effects
(Ryu et al., 2016).
THE COMPLEX TREATMENT OF LATE
ONSET ALZHEIMER’S DISEASE: MORE
THAN ANTIDIABETIC DRUGS
At least, a link between cognitive loss and T2DM involves
dysregulation of CNS circuits that control hepatic glucose
production. Thus, targeting these circuits could be a novel
potential strategy for the development of more effective
therapies resulting in both, improved glucose regulation and
cognitive performance. In this regard, our research group
has already discussed the potential cognitive benefits from
drugs originally addressed to treat T2DM (Batista et al.,
2019; Forny-Germano et al., 2019). Indeed, some molecules
used for the treatment of T2DM have shown neuroprotective
effects in preclinical models of AD. These drugs included
intranasal insulin, sulfonylureas, PPARγ agonists, metformin
and GLP-1 receptor agonists such as exendin-4, liraglutide
and lixisenatide (de la Monte, 2017; Cummings et al., 2018;
Batista et al., 2019). This opens a promising perspective for
these antidiabetic drugs. For instance, new formulations of
dual GLP-1/GIP, and the triple combination GLP-1/GCG/GIP
agonists, which are the most effective drugs for weight loss,
have been evaluated to treat LOAD (Camins et al., 2019).
Likewise, the pharmacological combination of GLP-1/GCG/GIP
has been shown to prevent the decline of brain glucose
metabolism in animal models (Capozzi et al., 2018). Molecularly,
the triagonist upregulated the expression of CREB, reverted
cognitive impairment and enhanced Long-term potentiation
(LTP) in preclinical models of AD (Tai et al., 2018). The
activation of CREB by phosphorylation at Ser133 (S133p-CREB)
is a critical step for memory formation and LTP maintenance
since the downstream genes are involved in synaptic formation,
neuronal plasticity and neurogenesis (Ettcheto et al., 2018a).
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FIGURE 2 | A suitable diet with natural products, for example rich in omega 3, antioxidants et cetera. can be a non-pharmacological complement for the prevention
of obesity. Therefore, it would also have effects on the decrease of peripheral and central inflammatory processes. This mechanism would have effects on the
prevention of central insulin resistance and improvement of the cognitive processes. The adherence over time to MedDiet would reduce the inflammatory levels in
brain, with a decrease in the generation of mitochondrial stress and JUN N-terminal Kinases-1 (JNK-1) activation. It would allow insulin receptor pathway to fine tune
the mitochondrial biogenesis according to the ATP/ADP intracellular balance of neuronal cells related to synaptogenesis and neuronal plasticity.
However, taking into account the multidisciplinary nature of
AD, more than one drug should be administered to reach a
complete treatment capable of slowing the neurodegenerative
process. Therefore, a combination of drugs that acts on
different pathways involved in the neuropathology of the
disease (i.e., amyloidogenic pathway, metabolism disorders,
excitotoxicity or neuroinflammation) could be the optimal
choice to treat AD. Furthermore, these drugs should be
administered as soon as possible to delay the process of
cognitive loss.
The antidiabetic drug pioglitazone has been evaluated for
AD treatment in the so-called TOMMORROW clinical trial
(ClinicalTrials.gov Identifier: NCT01931566). This phase III
study assess delay of onset of MCI-AD in cognitively normal
subjects between 65 and 83 years of age. The study has two
objectives: the first is a new genetic test to determine whether
participants are at risk of developing amild cognitive impairment
related to AD (MCI-AD) in the 5 years of study based on a
genetic biomarker composed of TOMM40 and APOE genotypes
and age used at the time of study incorporation. The second
objective is to evaluate the efficacy of pioglitazone to delay
the onset of MCI-AD in cognitively normal people who are at
high risk of developing MCI-AD (Roses et al., 2014). The study
will include 3,500 subjects. However, Takeda Pharmaceutical
Company Limited after a preliminary analysis of the results
reported that pioglitazone seems that was not effective in
MCI-AD prevention.
The studies evaluating the administration of nasal insulin in
the fight against forgetting (SNIFF) consists of a multicenter,
double-blind, placebo-controlled phase 2/3 trial sponsored by
the Cooperative Study of AD (ClinicalTrials.gov Identifier:
NCT01767909). The study aims to evaluate the efficacy of
intranasal administered insulin on cognition, entorhinal cortex
and hippocampal atrophy, and cerebrospinal fluid (CSF)
biomarkers in amnestic mild cognitive impairment (aMCI) or
mild AD. Thus, it will study AD biomarker profile, gender, or
APOE-ε4 allele carriage predict treatment response. According
to the hypothesis after 12 months of treatment with nasal insulin
compared to placebo, subjects would improve performance
on a global measure of cognition, on a memory composite
and on daily function. The results of the study have not yet
been published.
Finally, as we have previously stated, it has been reported
that Memantine improves the metabolic consequences produced
by HFD in the APP/PS1 mice model of familial AD (Ettcheto
et al., 2018b). These results demonstrate new possibilities into the
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role of Memantine not only in the occurrence of AD treatment,
but also into its potential application in peripheral metabolic
disorders where Aβ could play a role, as is the case of T2DM




In 2018, the group of Dr. Marta di Carlo published new results
in which they discussed the beneficial effects of a natural dietary
supplement (NDS) containingCurcuma longa, silymarin, guggul,
chlorogenic acid and inulin (Nuzzo et al., 2018). They showed
that NDS exerts neuroprotective effects in HFDmice by reducing
brain fat accumulation, oxidative stress and inflammation, as well
as by improving brain insulin resistance (Nuzzo et al., 2018).
Hence, it seems that dietary content can enhance or destabilize
the delicate machinery that allows neurons to survive, which
leads to the following question: could diet influence cognitive
performance in human populations?
As it is common in science, the answer goes probably
beyond a simple ‘‘yes’’ or ‘‘no,’’ but diet is indeed an important
modifiable lifestyle factor related to the development of many
pathologies and, among them there is all the different subtypes of
dementia (Gustafson et al., 2015). The studies leaded by Dr. Mia
Kivipelto were the first to show that beneficial midlife dietary
changes are associated with a reduced dementia risk later in
life (Sindi et al., 2018). Their results highlighted the importance
of targeting dietary patterns, describing how the combination
of determined food may have synergistic effects, thus further
potentiating their benefits. A meta-analysis by Hill et al. (2018,
2019) also revealed an effect of diet on AD biomarkers. With
2,726 records, the review supported the notion that diet and
nutrition display potential for non-pharmacological strategies
to improve the prognosis and prevent AD (Hill et al., 2018).
More recent investigations also showed the potential cerebral
benefits of diet interventions in human populations. For instance,
results from the Finnish Geriatric Intervention Study to Prevent
Cognitive Impairment and Disability (FINGER), which included
1,260 participants at-risk of cognitive decline (60–77 years),
allowed to conclude that, in fact, dietary changes seem to
play a key role in preventing cognitive loss (Lehtisalo et al.,
2019). In this study, the ingestion of a balanced diet was
associated with positive changes in executive function, especially
in the intervention group, after a 2-years follow-up. Hence,
these new approaches would show effects in the long term
and would be effective if they were to be followed for a long-
term. Thus, becoming complementary and preventive in the
long run.
This leads us to the next question: is there any particular
diet to adhere in order to prevent cognitive loss? In this regard,
a growing body of evidence associate the Mediterranean diet
(MedDiet) to preservation of cognitive performance in human
populations. MedDiet is characterized by a high intake of fruits,
vegetables, legumes, fish, whole grains, nuts, and olive oil, a
moderate consumption of dairy products and wine, and a low
intake of red and processed meats and foods that contain high
amounts of added sugars (Trichopoulou et al., 2003). Indeed,
recent results from non-Mediterranean populations suggest that
higher MedDiet adherence is associated with higher global
cognitive performance and brain structural integrity, as well as
decreased risk of AD and vascular dementia (VaD; Karstens
et al., 2019). In this line, the geographic location of our research
group allows us to describe our own experience from a closer
point of view, studying human populations naturally adhered to
MedDiet due to cultural reasons. The PREDIMED (in Spanish:
PREvención con DIeta MEDiterránea) study is a huge project
that has published more than 200 articles in indexed journals
during the last decade. The results from primary prevention trials
reported that long-term adherence to a MedDiet, supplemented
with either extra-virgin olive oil or nuts, reduced cardiovascular
disease (Hu et al., 2013). Also, other studies on the antioxidant
effects of walnuts proved evidence on their effects (Bulló et al.,
2010). The results from the PREDIMED project rapidly spread
through other metabolic aspects related to a MedDiet adherence.
Of note, Salas-Salvadó et al. (2016) reviewed the role of MedDiet
on preventing T2DM and stated that the role of the MedDiet
on the prevention and management of T2DM and metabolic
syndrome proves true according to the data of the study. In
turn,metabolomic studies allowed to identify plasma compounds
with potential to predict both insulin resistance and incident
T2DM (Papandreou et al., 2019). This is relevant since, both
in T2DM and LOAD, prevention could be a key factor, and
there is still a lack of clear molecular markers allowing to detect
at-risk candidates soon enough to reverse the damaging effects of
these diseases.
Conclusively, a PREDIMED study examined the effect
of T2DM on cognitive performance, specifically executive
function tasks, in a large cohort of 6,823 patients above
55 years of age (Mallorquí-Bagué et al., 2018). In this cross-
sectional study, T2DM (including illness duration), higher
Body Mass Index and lower mood were linked to lower
cognitive function in older individuals with conditions like
overweight/obesity and metabolic syndrome. Of note, MedDiet
includes a moderate intake of red wine and extra virgin
olive oil, both of them rich in polyphenolic compounds,
such as resveratrol, oleuropein, hydroxytyrosol and their
derivatives, which have shown anti-inflammatory effects on
microglia on in vitro and in vivo studies (Hornedo-Ortega
et al., 2018). According to these observations, it can be
hypothesized the adherence over time to MedDiet would
reduce the inflammatory levels in brain and the generation of
mitochondrial stress together with JNK-1 activation. It would
allow insulin receptor pathway to fine tune the mitochondrial
biogenesis according to the ATP/ADP intracellular balance
of neuronal cells related to synaptogenesis and neuronal
plasticity (Figure 2). By contrast, the exposure to high fat
diets, enriched in saturated fatty acids, would promote
the glial activation and mitochondrial oxidative stress. All
those stressing factors would activate JNK-1 resulting in an
impairment of insulin receptor pathway, causing and imbalance
in ATP/ADP levels and a failure to maintain the synaptic
connections (Figure 3). This hypothesis would explain how
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FIGURE 3 | The exposure to high fat diets over time, enriched in saturated fatty acids, would promote the glial activation and an increased mitochondrial oxidative
stress. All those stressing factors would activate JNK-1 resulting in an impairment of insulin receptor pathway, causing and imbalance in ATP/ADP levels and a failure
to control mitochondrial biogenesis and to maintain the synaptic connexions. This hypothesis would explain how JNK-1 should be a key factor linking diet and insulin
signaling to synaptogenesis failure.
JNK-1 should be a key factor linking diet and insulin signaling
to synaptogenesis failure.
Interestingly, one of the latest reports from the PREDIMED
project revealed changes in circulating MicroRNAs (miRNAs).
The GLYNDIET study is a 6-month, parallel, randomized clinical
trial conducted on overweight and obese subjects. Results from
GLYNDIET recently showed that the intake of an energy-
restricted low-glycaemic index diet down-regulates circulating
miRNA-361 more than an energy-restricted high-glycaemic
index, regardless of the magnitude of the weight loss Giardina
et al., 2019). Furthermore, Dr. Inestrosa stated in a seminal
review that miRNAs may be a molecular link in the complex
relationship between metabolic syndrome and AD (Codocedo
et al., 2016) and, a recent systematic review extracted all miRNAs
found to be significantly deregulated in peripheral blood and
cross-referenced them against the miRNAs deregulated in the
brain at Braak Stage III (Swarbrick et al., 2019). This resulted in
a group of 10 miRNAs; hsa-mir-107, hsa-mir-26b, hsa-mir-30e,
hsa-mir-34a, hsa-mir-485, hsa-mir200c, hsa-mir-210, hsa-mir-
146a, hsa-mir-34c, and hsa-mir-125b that could be potentially
involved in the regulation of these mechanisms. The authors
hypothesized that these molecular markers could be deregulated
early in AD, nearly 20 years before the emergence of clinical
symptoms (Swarbrick et al., 2019). Yet, PREDIMED results
on dysregulated circulating miRNAs in obesity and T2DM
do not match with those from AD patients. Despite these
negative preliminary observations, undoubtedly further studies
on circulating miRNAs could open a new therapeutic perspective
for patients affected by LOAD.
NEW PERSPECTIVES IN THE NEAR
FUTURE
As it has been discussed in this review article, recent results
frommultiple studies have contributed to reinforce the proposed
concept of T3D. In addition, from all the gathered data, it
is clear that targeting LOAD early stages, before widespread
neurodegeneration has occurred, is likely to produce the best
clinical outcome. However, detection of individuals at this stage
is still difficult. Consequently, new and reinforced efforts should
be made towards the discovery and description of biomarkers
that will allow for the early detection of pre-clinical candidates
for T2DM and/or LOAD. Clearly, a huge effort will be necessary
to overcome this molecular complexity just like in the new
formulation of new and more effective treatments for LOAD.
For now, it seems that the testing of more anti-T2DM drugs
with beneficial effects against cognitive impairment has a certain
promising future.
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